The Investor Sentiment - Equity and investments forum for Sri Lankans
Search
 
 

Display results as :
 


Rechercher Advanced Search

Latest topics
» Thread for News on Local and Foreign Politics
Today at 5:55 pm by Ethical Trader

» Thread for News on International Markets
Today at 1:58 pm by The Invisible

» AINS - Arpico Insurance
Yesterday at 10:43 am by The Invisible

» Thread for News on CSE and SL Economy
Yesterday at 7:28 am by serene

» CFVF - First Capital
Yesterday at 5:18 am by Ethical Trader

» Dividend Announcement
Wed Dec 12, 2018 6:07 pm by serene

» Obituary Notice.
Wed Dec 12, 2018 11:18 am by sashimaal

» BFN - Orient Finance
Wed Dec 12, 2018 9:34 am by PANTOMATH

» බඩගිනී
Tue Dec 11, 2018 9:20 am by Ethical Trader

» අනං මනං! #/+?.<>
Sun Dec 09, 2018 11:19 am by lanka

»  Rajgama heroes !
Sun Dec 09, 2018 9:43 am by කිත්සිරි ද සිල්වා

» BOPL.N0000 (Bogawantalawa Tea Estates PLC)
Fri Dec 07, 2018 7:35 am by The Invisible

» Sri Lanka economic slowdown trims company profits, bank earnings grow
Thu Dec 06, 2018 3:04 pm by nihal123

» JINS.N0000 ( Janashakthi Insurance PLC)
Thu Dec 06, 2018 10:05 am by The Invisible

» Better Than Bitcoin
Thu Dec 06, 2018 9:42 am by කිත්සිරි ද සිල්වා

» AAIC.N0000
Thu Dec 06, 2018 8:19 am by serene

» Hutchison, Etisalat complete mobile networks merger in Sri Lanka
Wed Dec 05, 2018 9:30 am by The Invisible

» Oil prices surge more than 5-pct
Mon Dec 03, 2018 1:53 pm by Ethical Trader

» Trading Journal
Mon Dec 03, 2018 11:33 am by lanka

» CCS.N0000 ( Ceylon Cold Stores)
Mon Dec 03, 2018 10:03 am by The Invisible

» HAYC - Haycarb
Sun Dec 02, 2018 3:04 pm by xmart

» In the Meantime, Within Our Shores !
Sat Dec 01, 2018 4:36 pm by කිත්සිරි ද සිල්වා

» LGL Laugfs Gas
Fri Nov 30, 2018 9:43 am by The Invisible

» Oil prices gain as investors eye Fed relief on interest rates
Fri Nov 30, 2018 9:41 am by The Invisible

» ලැයිස්තුගත සමාගම් 8 ක් කොටස් ගනුදෙනු තහනම් වීමේ අවදානමක
Thu Nov 29, 2018 11:34 am by nihal123

» අපි තනිකර ලෝකය දිව යන්නේ
Thu Nov 29, 2018 11:32 am by කිත්සිරි ද සිල්වා

» NDB.N0000 (NATIONAL DEVELOPMENT BANK PLC)
Thu Nov 29, 2018 10:32 am by The Invisible

» Orient Finance PLC--(Share_Valuation_Report)
Thu Nov 29, 2018 7:17 am by yellow knife

» කිඹුලා
Mon Nov 26, 2018 7:20 am by Lalinda

» Sandos' Vs Creators'
Sun Nov 25, 2018 1:17 pm by කිත්සිරි ද සිල්වා

» Tourists Arrival
Sat Nov 24, 2018 10:07 am by කිත්සිරි ද සිල්වා

» බිරිඳ
Fri Nov 23, 2018 11:49 am by Ethical Trader

» ගෙයක් හදන්නද ඉන්නේ
Fri Nov 23, 2018 5:55 am by Brave Heart

» --- සමෝසා වෙළෙන්දා -------
Fri Nov 23, 2018 5:51 am by Brave Heart

» විකුණුම්කරු
Sun Nov 18, 2018 2:10 pm by Ethical Trader

» Real Estate Market in Sri Lanka- A booming Industry or a Bubble?
Sun Nov 18, 2018 12:00 am by xmart

» Will YOU VOTE for ME if I run for SL PRESIDENCY?
Sat Nov 17, 2018 11:43 am by CK

» *කොට්ටේ තරණය කිරීම*
Fri Nov 16, 2018 6:25 pm by Ethical Trader

» COMB.N0000 ( COMMERCIAL BANK OF CEYLON PLC )
Wed Nov 14, 2018 9:20 pm by pjrngroup

» DIPD.N0000 (Dipped Products)
Wed Nov 14, 2018 7:18 am by The Invisible

» SAMP.N0000 (SAMPATH BANK PLC)
Wed Nov 14, 2018 7:16 am by The Invisible

» TAFL - Three Acre Farms
Wed Nov 14, 2018 7:14 am by The Invisible

» RCL - Royal Ceramics
Wed Nov 14, 2018 7:12 am by The Invisible

» HAYL.N0000 Hayleys PLC
Wed Nov 14, 2018 7:08 am by The Invisible

» How to trade Stock profitably?
Tue Nov 13, 2018 11:55 am by indramal

» What are investing methods in Sri Lanka?
Tue Nov 13, 2018 6:39 am by indramal

» Thread for General News Local/Foreign
Mon Nov 12, 2018 7:57 am by serene

» Anybody invest New York or Landon Stock Exchange?
Sat Nov 10, 2018 8:53 am by කිත්සිරි ද සිල්වා

» JKH.N0000
Fri Nov 09, 2018 10:49 am by ruwan326

» WATA - Watawala
Fri Nov 09, 2018 10:22 am by The Invisible

December 2018
SunMonTueWedThuFriSat
      1
2345678
9101112131415
16171819202122
23242526272829
3031     

Calendar Calendar

Disclaimer


Information posted in this forum are entirely of the respective members' personal views. The views posted on this open online forum of contributors do not constitute a recommendation buy or sell. The site nor the connected parties will be responsible for the posts posted on the forum and will take best possible action to remove any unlawful or inappropriate posts.
All rights to articles of value authored by members posted on the forum belong to the respective authors. Re-using without the consent of the authors is prohibited. Due credit with links to original source should be given when quoting content from the forum.
This is an educational portal and not one that gives recommendations. Please obtain investment advises from a Registered Investment Advisor through a stock broker

The Russians have come up with a vaccine against Ebola virus

Go down

The Russians have come up with a vaccine against Ebola virus

Post by AjithR on Tue Oct 14, 2014 4:03 pm

The Russians have come up with a vaccine against Ebola virus

In Russian laboratories are working on the preparation of a vaccine against Ebola virus testing in primates. On this, as reported by RIA Novosti, said Minister of Health Veronika Skvortsova.



"At the moment we have developed a vaccine of attenuated strains of topical. Currently works enough sufficient number of strains relevant to ensure that we could repeat the experiments on primates and go to clinical trials, "- said the Minister.

Total in Russia developed three vaccines. Finish work on them and move on to human trials planned for several months. According Skvortsova previously completed a full cycle of pre-clinical studies, but because of the obsolescence strains their applications does not make sense.

October 11 Minister in the program "Saturday News" reported that the citizens should not fear the spread of the virus in Russia. "Since March, in fact introduced a protection regime for Ebola in our country. In July of this mode is transferred to another level of protection, "- she said.

International experts say that the Ebola virus is likely to persist for a long time in West Africa. Unless drastic action is taken, the number of cases by the beginning of November 2014 may exceed 20,000.

Ebola outbreak was recorded in February 2014 in Guinea, and then the virus has spread in such African countries as Sierra Leone, Liberia, Nigeria, the Democratic Republic of Congo and Senegal. Individual cases of infection fever recorded in the United States and Europe. According to the World Health Organization, the total viral disease infected about 8,500 people, and died from it - more than four thousand.
http://bb.vesti.lv/obshchestvo/item/9159334-rossiyane-pridumali-vaktsinu-ot-virusa-eboly
avatar
AjithR

Posts : 256
Join date : 2014-09-15

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by The Alchemist on Tue Oct 14, 2014 5:07 pm


The Alchemist
Top contributor
Top contributor

Posts : 597
Join date : 2014-02-25

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by AjithR on Tue Oct 14, 2014 5:21 pm


The Political Economy of Ebola
by Leigh Phillips
6.91k
844
Ebola is a problem that will not be solved, because it isn’t profitable to do so.
Joseph Ferdinand Keppler / Library of Congress
Joseph Ferdinand Keppler / Library of Congress

The Onion, as ever, is on point with its “coverage” of the worst recorded outbreak of Ebola, and the first in West Africa, infecting some 1,779 people and killing at least 961. “Experts: Ebola Vaccine At Least 50 White People Away,” read the cheeky headline of the July 31 news brief.

Our shorthand explanation is that if the people infected with Ebola were white, the problem would be solved. But the market’s role in both drug companies’ refusal to invest in research and the conditions on the ground created by neoliberal policies that exacerbate and even encourage outbreaks goes unmentioned.

Racism is certainly a factor. Jeremy Farrar, an infectious disease specialist and the head of the Wellcome Trust, one of the largest medical research charities in the world, told the Toronto Star: “Imagine if you take a region of Canada, America, Europe, and you had 450 people dying of a viral hemorrhagic fever. It would just be unacceptable — and it’s unacceptable in West Africa.”

He noted how an experimental Canadian-developed Ebola vaccine had been provided on an emergency use basis to a German researcher in 2009 after a lab accident. “We moved heaven and earth to help a German lab technician. Why is it different because this is West Africa?”

But Ebola is a problem that is not being solved because there is almost no money to be made in solving it. It’s an unprofitable disease.

There have been around 2,400 people killed since Ebola was first identified in 1976. Major pharmaceutical companies know that the market for fighting Ebola is minute while the costs of developing treatment remain significant. On a purely quantitative basis, some might (perhaps rightly) warn against focusing too much on this one disease that kills far fewer than, for example, malaria (300,000 killed since the start of the Ebola outbreak) or tuberculosis (600,000).

Yet the economic constraints retarding progress in developing Ebola treatment also explain why drug companies are resisting developing treatment to those diseases as well as many others.

The last decade has actually seen a tremendous advance in research into therapies for Ebola, usually in the public sector or by small biotech companies with significant public funding, with a variety of treatment options on the table including nucleic-acid-based products, antibody therapies, and a number of candidate vaccines — five of which have successfully protected non-human primates from Ebola.

Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, has been telling everyone in the press who will listen to him in the last fortnight that an Ebola vaccine would be within spitting distance — if it weren’t for the corporate skinflints.

“We have been working on our own Ebola vaccine, but we never could get any buy-in from the companies,” he told USA Today.

“We have a candidate, we put it in monkeys and it looks good, but the incentive on the part of the pharmaceutical companies to develop a vaccine that treats little outbreaks every thirty or forty years — well, that’s not much incentive,” he told Scientific American.

Almost everyone familiar with the subject says that the know-how is there. It’s just that outbreaks are so rare and affect too few people for it to make development worthwhile — that is, profitable — for large pharmaceutical companies.

“These outbreaks affect the poorest communities on the planet. Although they do create incredible upheaval, they are relatively rare events,” Daniel Bausch, the director of the emerging infections department of Naval Medical Research Unit Six (NAMRU-6), a biomedical research laboratory in Lima, Peru, told Vox. “So if you look at the interest of pharmaceutical companies, there is not huge enthusiasm to take an Ebola drug through phase one, two, and three of a trial and make an Ebola vaccine that maybe a few tens of thousands or hundreds of thousands of people will use.”

John Ashton, president of the UK Faculty of Public Health, wrote a vituperative opinion piece in the Independent on Sunday decrying “the scandal of the unwillingness of the pharmaceutical industry to invest in research to produce treatments and vaccines, something they refuse to do because the numbers involved are, in their terms, so small and don’t justify the investment.

“This is the moral bankruptcy of capitalism acting in the absence of an ethical and social framework,” he concluded.

This situation is not unique to Ebola. For thirty years, the large pharmaceutical companies have refused to engage in research into new classes of antibiotics. Due to this “discovery void,” clinicians expect that within twenty years, we will have completely run out of effective drugs against routine infections. So many medical techniques and interventions introduced since the 1940s depend upon a foundation of antimicrobial protection. The gains in life expectancy that humanity has experienced over this time depended on many things, but would certainly not have been possible without antibiotics. Prior to their development, bacterial infections were one of the most common causes of death.

In April, the World Health Organization issued its first-ever report tracking antimicrobial resistance worldwide, finding “alarming levels” of bacterial resistance. “This serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country,” the UN health body warned.

The reason for this is straightforward, as the companies themselves themselves admit: It simply makes no sense to pharmaceutical companies to invest an estimated $870 million (or $1.8 billion accounting for the cost of capital) per drug approved by regulators on a product that people only use a handful of times in their life when suffering from an infection, compared to investing the same amount on the development of highly profitable drugs for chronic diseases such as diabetes or cancer that patients have to take every day, often for the rest of their lives.

Every year in the US, according to the CDC, some two million people are infected with antibiotic-resistant bacteria. 23,000 die as a result.

We see an identical situation with vaccine development. People purchase asthma drugs or insulin, for example, for decades, while vaccinations usually require only one or two doses once in a lifetime. For decades now, so many pharmaceutical companies have abandoned not just vaccine research and development but production as well, that by 2003, the US began to experience shortages of most childhood vaccines. The situation is so dire that the CDC maintains a public website tracking current vaccine shortages and delays.

But at least with respect to Ebola, where the market refuses to provide, the defense department is comfortable intervening and setting aside free-market principles in the interests of national security.

Virologist Thomas Geisbert of the University of Texas Medical Branch at Galveston told Scientific American about his hope for the VSV vaccine, one of the most promising options against Ebola:

We’re trying to get the funds to do the human studies … but it really depends on financial support for the small companies that develop these vaccines. Human studies are expensive and require a lot of government dollars. With Ebola, there’s a small global market — there’s not a big incentive for a large pharmaceutical company to make an Ebola vaccine, so it’s going to require government funding.

William Sheridan, the medical director of BioCryst Pharmaceuticals, the developer of experimental anti-viral drug BCX4430, describes the financial predicament facing Ebola treatment research and development: “It just wouldn’t make the cut at a major company.”

But for a small company like his, the federal government has both backed research and promised to purchase stockpiles of anti-Ebola drugs as a preventative measure against bioterrorism. BCX4430 is also co-developed with the US Army Medical Research Institute for Infectious Diseases (USAMRIID). “There is a market, and the market is the US government,” he told NPR.

USAMRIID, along with Canada’s Public Health Agency, is also backing the development of ZMAPP, a serum of monoclonal antibiodies by a small San Diego-based biotech firm MAPP Biopharmaceutical, which was administered last week to two American doctors, Kent Brantly and Nancy Writebol, working with the evangelical Christian missionary group Samaritan’s Purse.

The pair had fallen ill in Liberia while taking care of patients infected with Ebola. Brantley’s condition had been rapidly deteriorating, and he had phoned his wife to give his farewells. Within an hour of Brantley receiving the experimental serum, his condition had reportedly reversed, with his breathing improving and rashes fading.

The following morning, he was able to shower on his own, and by the time of his arrival in the US after being evacuated from Liberia, he was able to climb down out of the ambulance without assistance. Writebol is now similarly “up and walking,” after her arrival in Atlanta from the Liberian capital.

We should be extremely cautious about drawing any conclusions from this development and claiming that the drug has cured the missionaries. We have a sample size of just two in this “clinical trial,” with no blinding or control groups. The drug had until now never been tested on humans for safety or efficacy. And as with any illness, a certain percentage of patients will recover on their own. We do not know whether ZMapp was the cause of the apparent recovery. Nonetheless, it is not unreasonable to state that this turn of events gives great hope.

Two of the ZMapp antibodies were originally identified and developed by researchers at the National Microbiology Laboratory in Winnipeg and at Defyrus, a Toronto-based “life sciences biodefense company,” with funding from the Canadian Safety and Security Program of Defence R&D Canada. The third antibody in the cocktail was produced by MappBio in collaboration with USAMRIID, the National Institutes of Health, and the Defense Threat Reduction Agency. The companies then partnered with Kentucky Bioprocessing in Owensboro, a protein production company that was bought earlier this year by the parent firm of RJ Reynolds Tobacco, to pharm the antibody-laden tobacco plants.

On hearing of the role of the Pentagon and Canada’s defense establishment, some have jumped to conspiracy theories. Indeed, ZMapp appears to be a perfect storm of popular nemeses: GMOs, Big Tobacco, the Pentagon, and injections that look a bit like vaccines!

But the Defense Department funding should not be viewed as nefarious. Rather, it is evidence of the superiority of the public sector as shepherd and driver of innovation.

However, not all unprofitable diseases are subjects of the colonels’ bioterror concern. And why should the private sector get to cherry pick the profitable conditions and leave the unprofitable ones for the public sector?

If, due to its profit-seeking imperative, the pharmaceutical industry is structurally incapable of producing those products that are required by society, and the public sector (in this case in the guise of the military) consistently has to fill in the gaps left by this market failure, then this sector should be nationalized, permitting the revenues from profitable treatments to subsidize the research, development, and production of unprofitable treatments.

In such a situation, we would no longer have to even argue whether the prevention of malaria, measles, or polio deserves greater priority; we could target both the big name and neglected diseases at the same time. There is no guarantee that turning on the tap of public funding will immediately produce a successful result, but at the moment, private pharmaceutical companies aren’t even trying.

This is precisely what is meant when socialists talk of capitalism being a fetter on the further development of the forces of production. Our concern here is not merely that the refusal of Big Pharma to engage in neglected tropical disease, vaccine, and antibiotic R&D is grotesquely immoral or unjust, but that the production of a potential cornucopia of new goods and services that could otherwise benefit our species and expand the realm of human freedom are blocked due to the free market’s lethargy and paucity of ambition.

Focusing on a vaccine or drugs is critical. But doing so without also paying attention to the deterioration of public health and general infrastructure across West Africa, and the wider economic conditions that contribute to the likelihood of outbreaks of zoonotic diseases like Ebola, is at best using a bucket to empty the water out of a leaky and sinking boat.

Phylogeographer and ecologist Rob Wallace has described well how neoliberal fallout has established the ideal conditions for the epidemic. Guinea, Liberia, and Sierra Leone are some of the poorest countries on the planet, ranking 178th, 174th, and 177th out of 187 countries in the UN’s Human Development Index.

Were such an outbreak to occur in northern European countries, for example, nations with some of the best health infrastructure in the world, the situation would more likely have been contained.

It is not merely the dearth of field hospitals, lack of appropriate hygiene practices in existing hospitals, absence of standard isolation units, and limited cadre of highly trained health professionals that are able to track down every person that may have been exposed and isolate them. Or that better supportive care is a crucial condition of better outcomes, whatever the treatment available. The spread of the disease has also been exacerbated by a withering away of basic governmental structures that would otherwise be able to more broadly restrict movement, to manage logistical difficulties, and to coordinate with other governments.

Epidemiologist and infectious diseases specialist Daniel Bausch, who worked on research assignments near the epicenter of the current outbreak, describes in a paper published in July in the Public Library of Science journal Neglected Tropical Diseases how he “witnessed this ‘de-development’ firsthand; on every trip back to Guinea, on every long drive from Conakry to the forest region, the infrastructure seemed to be further deteriorated — the once-paved road was worse, the public services less, the prices higher, the forest thinner.”

Wallace notes that here, as in many countries, a series of structural adjustment programs have been encouraged and enforced by Western governments and international financial institutions that require privatization and contraction of government services, removal of tariffs while Northern agribusiness remains subsidized, and an orientation toward crops for export at the expense of food self-sufficiency. All of this drives poverty and hunger, and, in turn, competition between food and export crops for capital, land, and agricultural inputs leads to an ever greater consolidation of land ownership, in particular by foreign companies, that limits access of small farmers to land.

Ebola is a zoonotic disease, meaning a disease spread from animals to humans (or vice versa). Some 61 percent of human infections throughout history have been zoonotic, from influenza to cholera to HIV.

The single biggest factor driving growth in new zoonotic pathogens is increased contact between humans and wildlife, often by the expansion of human activity into wilderness. As neoliberal structural adjustment forces people off the land but without accompanying urban employment opportunities, Wallace points out, they plunge “deeper into the forest to expand the geographic as well as species range of hunted game and to find wood to make charcoal and deeper into mines to extract minerals, enhancing their risk of exposure to Ebola virus and other zoonotic pathogens in these remote corners.”

As Bausch puts it: “Biological and ecological factors may drive emergence of the virus from the forest, but clearly the sociopolitical landscape dictates where it goes from there — an isolated case or two or a large and sustained outbreak.”

These outcomes are the predictable result of unplanned, haphazard development in areas known to be the origin of zoonotic spillover, and without the sort of infrastructural support and egalitarian ethos that permitted, for example, the elimination of malaria from the American South after World War II by the CDC in one of its earliest missions.

Over these past few months, the worst Ebola outbreak in history has exposed the moral bankruptcy of our pharmaceutical development model. The fight for public health care in the United States and the allied fight against healthcare privatization elsewhere in the West has only ever been half the battle. The goal of such campaigns can only truly be met when a new campaign is mounted: to rebuild the international pharmaceutical industry as a public sector service as well as address wider neoliberal policies that indirectly undermine public health.

We could take inspiration from HIV/AIDS activist groups from the late 80s/early 90s like ACT UP and the Treatment Action Group, and, in the 2000s, South Africa’s Treatment Action Campaign, which combined direct action and civil disobedience against both companies and politicians with a scientifically rigorous understanding of their condition.

But this time, we need a larger, more comprehensive campaign covering not just one disease, but the panoply of market failures with respect to vaccine development, the antibiotic discovery void, neglected tropical diseases, and all neglected diseases of poverty. We need a science-based treatment activism that has the long-term, ambitious but achievable aim of the pharmaceutical industry’s democratic conquest.

We need a campaign to destroy the unprofitable diseases.
avatar
AjithR

Posts : 256
Join date : 2014-09-15

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by The Alchemist on Tue Oct 14, 2014 6:01 pm


The Alchemist
Top contributor
Top contributor

Posts : 597
Join date : 2014-02-25

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by The Alchemist on Tue Oct 14, 2014 6:23 pm

I would take the Ebola issue very very seriously - even from an Investment point of view - also for our market.

The Alchemist
Top contributor
Top contributor

Posts : 597
Join date : 2014-02-25

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by The Alchemist on Thu Oct 16, 2014 2:31 pm

http://nyti.ms/1CoENQw


Hope our Health Ministry is taking notes. This is serious stuff.

The Alchemist
Top contributor
Top contributor

Posts : 597
Join date : 2014-02-25

Back to top Go down

Re: The Russians have come up with a vaccine against Ebola virus

Post by AjithR on Thu Oct 16, 2014 2:55 pm

Ten things you should know about Ebola
Ebola belongs to a group of diseases known as haemorrhagic fever and is the world's most deadly viral disease. The outbreak under way in West Africa right now is the most extensive since the disease was discovered in the 1970s. The echo here list ten things you should keep an eye on Ebola.


How did the disease and how did the current outbreak in West Africa?
The virus has been transmitted to humans from wild animals and bats of the genus  Pteropodidae  deemed to be the natural host of the Ebola virus. disease first detected in humans in 1976 in what was then Zaire (now the Democratic Republic of Congo), and has essentially claimed casualties in isolated villages in the jungle areas in central Africa.

The outbreak raging in West Africa is now the most extensive since the disease was discovered. It arose in south-eastern Guinea in early 2014 and then spread to several regions of Guinea and also to the neighbouring countries of Sierra Leone and Liberia, where the situation right now is that serious.
How contagious Ebola?
It is found that Ebola is transmitted via bodily fluids, but the question of whether the virus can mutate and become airborne has been up.
- We now have looked at viruses and other infectious diseases for 100 years and it has never happened before. Virus alters not terribly radical, the only development we can possibly see is that they become less infectious, says Anders Tegnell, state epidemiologist at the Public Health Agency.

The incubation period is up to three weeks and symptoms of the disease are high fever, headache, muscle pain, and diarrhea. At a later stage of the disease can be bleeding from all orifices, follow, and the internal organs can be dissolved.

Can also be infected by the subject as an Ebola infection have stayed in?

- This happens under the care and management of giant sick or dead people. Have a sick person's fluids and blood landed on a sheet and then put on the sheet five minutes later, it is of course not impossible that they are infected.   One should of course be very careful with items that have been soiled in a care situation, they will be disposed of according to the rules and routines.


A limited number of cases have been found in Nigeria ( initially around an Ebola ill man who traveled from Liberia) and one case in Senegal. The DRC has been in 2014 had over 60 confirmed cases, but they do not seem to have any connection to the epidemic in West Africa.

A few cases have been found in European countries such as Norway, Spain and Germany - where it's about people infected in the countries affected or infected when they tended Ebola disease. Also in the USA, a few cases found by the same causes.
http://sverigesradio.se/sida/artikel.aspx?programid=83&artikel=5992176
avatar
AjithR

Posts : 256
Join date : 2014-09-15

Back to top Go down

Back to top


 
Permissions in this forum:
You cannot reply to topics in this forum